KR20210116432A - 화학요법으로 유발된 메스꺼움 및 구토 치료를 위한 방법 및 제형 - Google Patents

화학요법으로 유발된 메스꺼움 및 구토 치료를 위한 방법 및 제형 Download PDF

Info

Publication number
KR20210116432A
KR20210116432A KR1020217013980A KR20217013980A KR20210116432A KR 20210116432 A KR20210116432 A KR 20210116432A KR 1020217013980 A KR1020217013980 A KR 1020217013980A KR 20217013980 A KR20217013980 A KR 20217013980A KR 20210116432 A KR20210116432 A KR 20210116432A
Authority
KR
South Korea
Prior art keywords
formulation
patient
day
chemotherapy
thc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217013980A
Other languages
English (en)
Korean (ko)
Inventor
캐서린 제이콥슨
Original Assignee
틸레이, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 틸레이, 인크. filed Critical 틸레이, 인크.
Publication of KR20210116432A publication Critical patent/KR20210116432A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217013980A 2018-10-10 2019-10-10 화학요법으로 유발된 메스꺼움 및 구토 치료를 위한 방법 및 제형 Withdrawn KR20210116432A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743839P 2018-10-10 2018-10-10
US62/743,839 2018-10-10
PCT/US2019/055662 WO2020077103A1 (en) 2018-10-10 2019-10-10 Methods and formulations for treating chemotherapy-induced nausea and vomiting

Publications (1)

Publication Number Publication Date
KR20210116432A true KR20210116432A (ko) 2021-09-27

Family

ID=68345091

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217013980A Withdrawn KR20210116432A (ko) 2018-10-10 2019-10-10 화학요법으로 유발된 메스꺼움 및 구토 치료를 위한 방법 및 제형

Country Status (12)

Country Link
US (1) US20200113847A1 (enExample)
EP (1) EP3863614A1 (enExample)
JP (1) JP2022502471A (enExample)
KR (1) KR20210116432A (enExample)
AU (1) AU2019357608A1 (enExample)
BR (1) BR112021006858A2 (enExample)
CA (1) CA3115985A1 (enExample)
CL (1) CL2021000882A1 (enExample)
CO (1) CO2021005797A2 (enExample)
MX (1) MX2021004138A (enExample)
PE (1) PE20211198A1 (enExample)
WO (1) WO2020077103A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3969054A4 (en) * 2019-05-16 2023-09-06 Aegis Therapeutics, LLC COMPOSITIONS CONTAINING OIL-SOLUBLE DRUGS AND METHODS OF USING SUCH COMPOSITIONS
JP7883957B2 (ja) 2020-05-18 2026-07-02 マックス バイオロジー カンパニー リミテッド 脂質ポリマー組成物及び使用方法
AU2021347760B2 (en) * 2020-09-24 2024-07-25 Nicoventures Trading Limited Formulation
US20240252464A1 (en) * 2022-07-06 2024-08-01 Avantsar Sdn Bhd A self-emulsifying drug delivery formulation with improved oral bioavailability of lipophilic compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20040248970A1 (en) * 2003-04-10 2004-12-09 Webster G.R. Barrie CBD-delta8-THC composition
EP1706098A4 (en) * 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICRO-LAYER SYSTEMS FOR THE TRANSPORT OF LIPOPHILES AND BZW. HYDROPHOBIC COMPOUNDS
BRPI0610364A2 (pt) * 2005-05-13 2010-06-15 Unimed Pharmaceuticals Inc tratamento, com dronabinol, de náusea e vÈmito retardados induzidos por quimioterapia
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
RU2016129536A (ru) * 2013-10-31 2018-01-31 Фулл Спектрум Лабораториз, Лтд. Препараты на основе терпенов и каннабиноидов
WO2017203529A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
AU2017334283A1 (en) * 2016-09-27 2019-04-04 CannTab Therapeutics Limited Sustained release cannabinoid formulations
US20200163931A1 (en) * 2016-10-12 2020-05-28 Columbia Care Llc Oral composition of extracted cannabinoids and methods of use thereof
EA201991641A1 (ru) * 2017-01-03 2020-03-10 Ресептор Холдингз, Инк. Лекарственные соединения и пищевые добавки
WO2018152334A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
US10307392B2 (en) * 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
WO2019100007A1 (en) * 2017-11-17 2019-05-23 Tilray, Inc. Cannabinoid compositions
WO2019165387A1 (en) * 2018-02-23 2019-08-29 Spirtos Nicola Michael Cannabis based therapeutic and method of use
CA3107014A1 (en) * 2018-07-31 2020-02-06 AusCann Group Holdings Ltd Solid self-emulsifying pharmaceutical compositions

Also Published As

Publication number Publication date
MX2021004138A (es) 2021-08-05
WO2020077103A1 (en) 2020-04-16
PE20211198A1 (es) 2021-07-01
US20200113847A1 (en) 2020-04-16
AU2019357608A1 (en) 2021-05-27
JP2022502471A (ja) 2022-01-11
CO2021005797A2 (es) 2021-05-20
BR112021006858A2 (pt) 2021-07-13
CA3115985A1 (en) 2020-04-16
EP3863614A1 (en) 2021-08-18
CL2021000882A1 (es) 2021-08-27

Similar Documents

Publication Publication Date Title
JP7394974B2 (ja) 酢酸アビラテロンを含む医薬組成物、並びにその製造方法及び使用
DK2600851T3 (en) PHARMACEUTICAL DOSAGE FORM CONTAINING 6'-FLUORO- (N-METHYL OR N, N-DIMETHYL -) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PYRANO [3,4, B] INDOL] -4-AMINE FOR TREATMENT OF NEUROPATHIC PAIN
EP3248599B1 (en) Omega-3 fatty acid self-emulsifying composition
JP2020011958A (ja) ω３脂肪酸の自己乳化組成物
CN101596177B (zh) 辅酶q10自乳化组合物及其制备方法与应用
US20040110828A1 (en) Tetrahydrocannabinol compositions and methods of manufacture and use thereof
WO2009012718A1 (en) A composite emulsifier, an emulsion prepared from it and the preparation method thereof
US20200113847A1 (en) Methods and formulations for treating chemotherapy-induced nausea and vomiting
KR101025641B1 (ko) 매스틱 자가유화에멀젼 조성물 및 이를 함유하는 캡슐
JP2006508104A (ja) 難溶性風邪薬の経口投与用マイクロエマルション濃縮液及びその製造方法
US20230330110A1 (en) Hard capsule dosage form and uses thereof
BRPI0008228B1 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
CN106074377A (zh) 一种稳定型维生素k2亚微乳及其制备方法
US20220023314A1 (en) Stable formulations of anesthetics and associated dosage forms
CN112168781B (zh) 他克莫司的自微乳组合物及其制备方法
US20050249803A1 (en) Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
CN107281106B (zh) 胆酸盐修饰的阳离子维生素d3口服脂质体及其冻干制剂
US20060276436A1 (en) Farnesyl dibenzodiazepinone formulation
CN1287773C (zh) 一种鸦胆子油软胶囊制剂
CN1739519B (zh) 伊曲康唑注射乳剂及其制备方法
KR101058860B1 (ko) 수소화 코코-글리세라이드를 이용한 난용성 약물의 자가유화형 나노에멀젼 조성물
CN110339164A (zh) 酮咯酸酯类衍生物静脉注射脂肪乳剂、制备方法和应用
CN1895262B (zh) 表阿霉素注射用乳剂及制备方法
WO2012066347A1 (en) Oil based formulations
HK40118320A (en) Pharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210510

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221006

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20230518

WITB Written withdrawal of application